Distinguished Scientist
Merck Research Laboratories
Rahway, New Jersey
Kevin Gurney received a PhD in Microbiology and Immunology at University of California of Los Angeles Jan 2002 performing reserach work in HIV-1 pathogenesis in the thymus and postdoctoral research in HIV-1 transmission via interaction with mucosal dendritic cells via DC-SIGN. Kevin began his biotech career in the Discovery Immunoogy Group developing biologics for myeloid cell targets in models of arthritis and cancer. In 2009, Kevin joined a Merck Bioventures Pharmacology Group breifly before spending the majority of his career in CMC analytical development organization leading bioassay groups, leading product development teams to drive regulatory submissions for key pipeline drugs for biotherapeutics and vaccines.. Kevin spent a brief time in a start up cel therapy company as vice president guiding development strategy. Currently, Kevin is currently a Distinguished Scientist within the Analytical Research and Development organization at Merck driving scientific strategy for structure function characterization of Merck's large molecule pipeline, immunogenicity assessments of product attributes, and promoting sceintific development within the department and across partner groups Kevin is a memer of AAPS and committee leader in the Biopharmaceutical Product Attributes and Biologic Consequences.
Disclosure information not submitted.
Analytical Control Strategy for Half-Life Extension Features of Biotherapeutics
Tuesday, November 11, 2025
10:30 AM - 11:00 AM CT